CN105232448A - 控释药物组合物 - Google Patents

控释药物组合物 Download PDF

Info

Publication number
CN105232448A
CN105232448A CN201510642287.2A CN201510642287A CN105232448A CN 105232448 A CN105232448 A CN 105232448A CN 201510642287 A CN201510642287 A CN 201510642287A CN 105232448 A CN105232448 A CN 105232448A
Authority
CN
China
Prior art keywords
controlled release
pharmaceutical compositions
release pharmaceutical
weight
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510642287.2A
Other languages
English (en)
Chinese (zh)
Inventor
高石勇希
高桥丰
西里崇
村山大辅
村山惠美子
中村聪一郎
迫和博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105232448(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of CN105232448A publication Critical patent/CN105232448A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201510642287.2A 2008-09-30 2009-09-28 控释药物组合物 Pending CN105232448A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10133808P 2008-09-30 2008-09-30
US61/101,338 2008-09-30
CN2009801386919A CN102170878A (zh) 2008-09-30 2009-09-28 控释药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801386919A Division CN102170878A (zh) 2008-09-30 2009-09-28 控释药物组合物

Publications (1)

Publication Number Publication Date
CN105232448A true CN105232448A (zh) 2016-01-13

Family

ID=42073454

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510642287.2A Pending CN105232448A (zh) 2008-09-30 2009-09-28 控释药物组合物
CN2009801386919A Pending CN102170878A (zh) 2008-09-30 2009-09-28 控释药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801386919A Pending CN102170878A (zh) 2008-09-30 2009-09-28 控释药物组合物

Country Status (24)

Country Link
US (4) US20160184275A2 (https=)
EP (2) EP2345410B1 (https=)
JP (2) JP4688089B2 (https=)
KR (1) KR101524164B1 (https=)
CN (2) CN105232448A (https=)
AU (1) AU2009300752C1 (https=)
BR (1) BRPI0919466B1 (https=)
CA (1) CA2740342C (https=)
CY (1) CY1123724T1 (https=)
DK (1) DK2345410T3 (https=)
ES (1) ES2847876T3 (https=)
HK (1) HK1216232A1 (https=)
HR (1) HRP20210179T1 (https=)
HU (1) HUE052874T2 (https=)
IL (1) IL212033A (https=)
LT (1) LT2345410T (https=)
MX (1) MX351855B (https=)
PL (1) PL2345410T3 (https=)
PT (1) PT2345410T (https=)
RU (1) RU2495666C2 (https=)
SI (1) SI2345410T1 (https=)
TW (1) TWI478712B (https=)
WO (1) WO2010038690A1 (https=)
ZA (1) ZA201102406B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446490A (zh) * 2017-03-17 2019-11-12 株式会社钟根堂 包含米拉贝隆或其盐的用于调节释放的药剂学组合物

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281042B6 (sk) * 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
ES2665467T3 (es) * 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
JP6272695B2 (ja) 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
WO2013058409A1 (en) * 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
JP6123795B2 (ja) * 2012-03-30 2017-05-10 アステラス製薬株式会社 放出制御医薬組成物
EP2832730A4 (en) 2012-03-30 2015-09-09 Astellas Pharma Inc MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
CA2883270A1 (en) * 2012-08-31 2014-03-06 Astellas Pharma Inc. Orally administered medical composition
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
CN104523635B (zh) * 2014-12-23 2017-05-03 深圳万乐药业有限公司 米拉贝隆缓释药物组合物
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) * 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
EP3448367A1 (en) 2016-04-25 2019-03-06 Synthon BV Tablets comprising mirabegron and solifenacin
US10543174B2 (en) 2016-04-25 2020-01-28 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3360866B1 (en) 2017-02-14 2019-01-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR20170088783A (ko) * 2017-07-07 2017-08-02 지엘팜텍주식회사 미라베그론의 습식과립 조성물
KR101937713B1 (ko) * 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
CA3078568A1 (en) * 2017-10-12 2019-04-18 Synthon B.V. Modified release tablet composition comprising mirabegron
US10478399B2 (en) * 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3292864A1 (en) * 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron
KR20190089758A (ko) 2018-01-22 2019-07-31 (주)동구바이오제약 미라베그론 또는 이의 약제학적으로 허용가능한 염을 함유하는 지속 방출 제제
KR102371567B1 (ko) 2018-04-06 2022-03-07 한미약품 주식회사 미라베그론이 함유된 방출 제어 약학적 조성물
KR102659760B1 (ko) 2018-10-18 2024-04-23 한미약품 주식회사 미라베그론이 함유된 방출 제어 약제학적 조성물
KR102062791B1 (ko) 2019-02-26 2020-01-06 신일제약 주식회사 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제
KR102897443B1 (ko) 2019-06-28 2025-12-08 한미약품 주식회사 제어 방출형 미라베그론 제제 및 이의 제조방법
JP7377782B2 (ja) * 2019-09-04 2023-11-10 信越化学工業株式会社 フィルム成形用組成物及びフィルム
TW202140010A (zh) * 2020-01-31 2021-11-01 日商日本新藥股份有限公司 控釋組合物
KR102546923B1 (ko) * 2020-03-03 2023-06-26 동광제약 주식회사 미라베그론을 포함하는 제어 방출 제제
CN113662922A (zh) * 2020-10-29 2021-11-19 北京莱瑞森医药科技有限公司 一种米拉贝隆缓释组合物及其制备方法和应用
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
CN114306262B (zh) * 2021-12-30 2023-09-05 乐泰药业有限公司 米拉贝隆缓释片及其制备方法和质量检测方法
EP4338729A1 (en) * 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
JP7820861B2 (ja) * 2024-01-26 2026-02-26 富士化学工業株式会社 徐放性製剤
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2025263523A1 (ja) * 2024-06-21 2025-12-26 沢井製薬株式会社 ミラベグロン含有製剤
WO2026064392A1 (en) 2024-09-17 2026-03-26 Flavostar Llc Fixed dose combination of flavoxate and beta-3 adrenergic receptor agonists, and formulations and manufacturing processes thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006414A1 (fr) * 1992-09-18 1994-03-31 Yamanouchi Pharmaceutical Co., Ltd. Preparation d'hydrogel a liberation prolongee
WO2004041276A1 (ja) * 2002-11-07 2004-05-21 Yamanouchi Pharmaceutical Co., Ltd. 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JPH03145418A (ja) 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
GB9111426D0 (en) 1991-05-28 1991-07-17 Ici Plc Chemical compounds
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
ES2107235T3 (es) 1993-06-14 1997-11-16 Janssen Pharmaceutica Nv Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
HUT77530A (hu) 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
JP4685201B2 (ja) 1996-08-19 2011-05-18 キッセイ薬品工業株式会社 頻尿および尿失禁の予防・治療剤
EP1014957A4 (en) 1997-08-28 2004-01-28 Afferon Corp URINARY INCONTINENCE THERAPY
ATE266639T1 (de) * 1997-10-17 2004-05-15 Yamanouchi Pharma Co Ltd Amidderivate oder deren salze
WO1999031045A1 (en) 1997-12-18 1999-06-24 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
DE69919860T2 (de) 1998-04-14 2005-08-25 Kissei Pharmaceutical Co., Ltd., Matsumoto 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
HU229295B1 (en) 1999-08-04 2013-10-28 Astellas Pharma Inc Stable medicinal compositions for oral use
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6368628B1 (en) 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
CN1469876A (zh) 2000-10-20 2004-01-21 �Ʒ� α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US20030072802A1 (en) 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
JP2005512997A (ja) 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠
KR20040066177A (ko) * 2001-12-19 2004-07-23 알자 코포레이션 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1503732B1 (en) 2002-04-29 2008-10-08 Alza Corporation Reduced formate poly(alkylene oxides) with reboxetine for reducing impurity formation
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
AU2004224322A1 (en) 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
KR101192722B1 (ko) 2003-04-24 2012-10-18 자고텍 아게 정해진 핵 위치를 가지는 서방성 정제
US20050042289A1 (en) 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
DE602004030931D1 (https=) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
US8128958B2 (en) 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
JP2005162737A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
JP2005162736A (ja) 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
US8197846B2 (en) 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
NZ551118A (en) 2004-05-24 2010-09-30 Warner Chilcott Co Llc Enteric solid oral dosage form of bisphosphonate containing a chelating agent
EA011446B1 (ru) 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
US20050287185A1 (en) 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
US20080095841A1 (en) 2004-10-06 2008-04-24 Eisai R&D Management Co., Ltd. Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
BRPI0608573A2 (pt) 2005-03-08 2017-07-25 Lifecycle Pharma As Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
JP5124286B2 (ja) 2006-01-10 2013-01-23 キッセイ薬品工業株式会社 徐放性製剤およびその製造方法
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009052353A2 (en) 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Trospium pharmaceutical formulations
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011122523A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
WO2012047530A1 (en) 2010-09-28 2012-04-12 International Business Machines Corporation Providing answers to questions using logical synthesis of candidate answers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006414A1 (fr) * 1992-09-18 1994-03-31 Yamanouchi Pharmaceutical Co., Ltd. Preparation d'hydrogel a liberation prolongee
WO2004041276A1 (ja) * 2002-11-07 2004-05-21 Yamanouchi Pharmaceutical Co., Ltd. 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446490A (zh) * 2017-03-17 2019-11-12 株式会社钟根堂 包含米拉贝隆或其盐的用于调节释放的药剂学组合物
CN110446490B (zh) * 2017-03-17 2023-04-04 株式会社钟根堂 包含米拉贝隆或其盐的用于调节释放的药剂学组合物

Also Published As

Publication number Publication date
AU2009300752B2 (en) 2013-12-19
US20240277675A1 (en) 2024-08-22
EP2345410B1 (en) 2020-12-30
EP2345410A4 (en) 2014-12-03
BRPI0919466B1 (pt) 2021-05-25
US10842780B2 (en) 2020-11-24
DK2345410T3 (da) 2021-02-01
BRPI0919466A2 (pt) 2015-12-01
JP2011079859A (ja) 2011-04-21
HRP20210179T1 (hr) 2021-05-28
JP5625855B2 (ja) 2014-11-19
AU2009300752C1 (en) 2024-01-04
RU2011117274A (ru) 2012-11-10
MX351855B (es) 2017-10-31
HUE052874T2 (hu) 2021-05-28
ES2847876T3 (es) 2021-08-04
EP3827826A1 (en) 2021-06-02
IL212033A0 (en) 2011-06-30
TWI478712B (zh) 2015-04-01
US20210322387A1 (en) 2021-10-21
PT2345410T (pt) 2021-02-08
JP4688089B2 (ja) 2011-05-25
CA2740342C (en) 2016-05-03
JPWO2010038690A1 (ja) 2012-03-01
ZA201102406B (en) 2012-06-27
AU2009300752A1 (en) 2010-04-08
CY1123724T1 (el) 2022-05-27
RU2495666C2 (ru) 2013-10-20
US20100144807A1 (en) 2010-06-10
HK1216232A1 (zh) 2016-10-28
KR101524164B1 (ko) 2015-06-01
CA2740342A1 (en) 2010-04-08
CN102170878A (zh) 2011-08-31
KR20110071103A (ko) 2011-06-28
US20160184275A2 (en) 2016-06-30
EP2345410A1 (en) 2011-07-20
SI2345410T1 (sl) 2021-03-31
US20170231965A1 (en) 2017-08-17
WO2010038690A1 (ja) 2010-04-08
PL2345410T3 (pl) 2021-07-05
US12059409B1 (en) 2024-08-13
TW201023857A (en) 2010-07-01
IL212033A (en) 2016-08-31
LT2345410T (lt) 2021-02-25
MX2011003445A (es) 2011-05-02

Similar Documents

Publication Publication Date Title
CN105232448A (zh) 控释药物组合物
CN101163479B (zh) 固体药物剂型
EP4066821B1 (en) Tablet formulations of neratinib maleate
CN104922683A (zh) 含有蜡的缓释制剂
CN104602693A (zh) 口服给药用药物组合物
EP2964200B1 (en) Formulations of organic compounds
CN102307579A (zh) 经口给药用医药组合物
EP1771161A1 (en) Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
KR20080076440A (ko) 실로스타졸의 제어방출 제제 및 그 제조방법
US20140335176A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
CN102292075B (zh) 包含hcv聚合酶抑制剂前药的药物组合物
WO2018108151A1 (zh) 一种维利帕尼缓控释药物组合物及其用途
WO2007018190A1 (ja) 苦味抑制製剤
US20230048901A1 (en) Solid oral formulation of utidelone
CN108653218A (zh) 作为alk/fak/igf1r多激酶抑制剂的吡咯并嘧啶衍生物的药物制剂组合物及其制备方法
CN113164455B (zh) 难溶性药物的固体分散体
CN114209668A (zh) 一种盐酸阿夫唑嗪缓释制剂及其制备方法
RU2670447C2 (ru) Пероральная твердая лекарственная форма с микофенольной кислотой или ее солью для использования в качестве иммунодепрессанта для лечения или предупреждения отторжения трансплантата органа или ткани и способ ее получения
JPWO1997033571A1 (ja) エカドトリルの速放微分散性製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1216232

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160113

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1216232

Country of ref document: HK